OBJECTIVES: To evaluate the representation of frail older adults in randomized controlled trials (RCTs), and to assess consequences of under representation by analyzing drug discontinuation rates. METHODS: A cohort of older adults newly dispensed donepezil in Ontario between September 2001 and March 2002 was constructed using administrative data. A systematic review of the literature identified RCTs of donepezil. Patients dispensed donepezil were then compared to clinical trial subjects. Discontinuation rates were examined for patients with and without potential contraindications to this drug. RESULTS: There were 6,424 older adults in the Ontario cohort with new claims for donepezil. Ten RCTs evaluating the use of donepezil were identified (n = 3,423). Between 51% and 78% of the Ontario cohort would have been ineligible for RCT enrollment. Patients dispensed donepezil were older (80.3 vs. 73.7 years, p < 0.001) and more likely to be in long-term care (14.1 vs. 7.1%, p < 0.001) than RCT subjects. Overall, 27.8% of the Ontario cohort discontinued donepezil within seven months of initial prescription. Discontinuation rates were significantly higher for patients with a history of obstructive lung disease, active cardiovascular disease, or Parkinsonism. CONCLUSIONS: Fewer than half of the older adults dispensed donepezil in Ontario would have been eligible to participate in the RCTs that established the efficacy of this drug. Discontinuation rates were higher among patient groups not represented in the trials. Clinicians should carefully assess the potential risks and benefits of such drug therapies for older patients with dementia.
OBJECTIVES: To evaluate the representation of frail older adults in randomized controlled trials (RCTs), and to assess consequences of under representation by analyzing drug discontinuation rates. METHODS: A cohort of older adults newly dispensed donepezil in Ontario between September 2001 and March 2002 was constructed using administrative data. A systematic review of the literature identified RCTs of donepezil. Patients dispensed donepezil were then compared to clinical trial subjects. Discontinuation rates were examined for patients with and without potential contraindications to this drug. RESULTS: There were 6,424 older adults in the Ontario cohort with new claims for donepezil. Ten RCTs evaluating the use of donepezil were identified (n = 3,423). Between 51% and 78% of the Ontario cohort would have been ineligible for RCT enrollment. Patients dispensed donepezil were older (80.3 vs. 73.7 years, p < 0.001) and more likely to be in long-term care (14.1 vs. 7.1%, p < 0.001) than RCT subjects. Overall, 27.8% of the Ontario cohort discontinued donepezil within seven months of initial prescription. Discontinuation rates were significantly higher for patients with a history of obstructive lung disease, active cardiovascular disease, or Parkinsonism. CONCLUSIONS: Fewer than half of the older adults dispensed donepezil in Ontario would have been eligible to participate in the RCTs that established the efficacy of this drug. Discontinuation rates were higher among patient groups not represented in the trials. Clinicians should carefully assess the potential risks and benefits of such drug therapies for older patients with dementia.
Authors: Kathryn Richardson; George M Savva; Penelope J Boyd; Clare Aldus; Ian Maidment; Eduwin Pakpahan; Yoon K Loke; Antony Arthur; Nicholas Steel; Clive Ballard; Robert Howard; Chris Fox Journal: Health Technol Assess Date: 2021-01 Impact factor: 4.014
Authors: Anne Stephenson; Dallas P Seitz; Hadas D Fischer; Andrea Gruneir; Chaim M Bell; Andrea S Gershon; Longdi Fu; Geoff M Anderson; Peter C Austin; Paula A Rochon; Sudeep S Gill Journal: Drugs Aging Date: 2012-03-01 Impact factor: 3.923
Authors: Lona Mody; Douglas K Miller; Joanne M McGloin; Marcie Freeman; Edward R Marcantonio; Jay Magaziner; Stephanie Studenski Journal: J Am Geriatr Soc Date: 2008-12 Impact factor: 5.562
Authors: Colleen J Maxwell; Mary Vu; David B Hogan; Scott B Patten; Micaela Jantzi; Marie-Jeanne Kergoat; Nathalie Jetté; Susan E Bronskill; George Heckman; John P Hirdes Journal: Drugs Aging Date: 2013-07 Impact factor: 3.923
Authors: Laura Y Park-Wyllie; Muhammad M Mamdani; Ping Li; Sudeep S Gill; Andreas Laupacis; David N Juurlink Journal: PLoS Med Date: 2009-09-29 Impact factor: 11.069